Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia
NCT01854918
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
3681
Enrollment
INDUSTRY
Sponsor class
Conditions
Hyperlipidemia and Mixed Dyslipidemia
Interventions
BIOLOGICAL:
Evolocumab
DRUG:
Standard of Care
Sponsor
Amgen